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Background: Insulin detemir, a long-acting basal insulin analog, is labeled for once-daily 
or twice-daily dosing in patients with type 1 (T1DM) or type 2 (T2DM) diabetes mellitus. 
  Protocols for some earlier clinical studies of detemir evaluated twice-daily dosing, which 
may have generated the misperception that detemir should be prescribed twice daily for most 
patients. This review examines pharmacokinetic and pharmacodynamic (PK/PD), observational, 
and controlled studies that have evaluated once-daily and twice-daily detemir in patients with 
T2DM to determine the efficacy and safety of once-daily dosing.
Methods: PubMed was searched using the keywords “detemir,” “once daily,” “twice daily,” 
and “type 2 diabetes” with the limits of clinical trial, human, and English.
Results: Detemir has a relatively flat time–action profile and duration of action of up to 24 hours 
for patients with T2DM. Once-daily dosing is the most commonly used detemir regimen 
reported in observational studies, and controlled clinical studies indicate that once-daily dosing 
controls glycosylated hemoglobin when detemir is administered alone or in combination with a 
prandial insulin or oral antidiabetes drugs. In comparative clinical trials, detemir had a similar 
time–action profile and duration of action to another long-acting insulin analog, glargine, with 
less within-subject variability. Once-daily detemir was associated with no weight gain or less 
weight gain than comparator regimens. For patients who had not achieved glycemic control with 
a basal dose of once-daily detemir, adding a prandial insulin provided better glycemic control, 
less postprandial hypoglycemia, and a lower total daily dose of detemir than twice-daily detemir. 
Involvement of a multidisciplinary team and the use of a holistic approach for the treatment of 
T2DM patients are recommended to achieve and maintain the best patient outcomes.
Conclusion: Results from PK/PD, observational, and controlled clinical studies support 
a once-daily detemir regimen alone or in combination with a prandial insulin or oral antidi-
abetes drugs.
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Introduction
The joint American Diabetes Association/European Association for the Study of 
  Diabetes (ADA/EASD) 2009 consensus algorithm for initiation and adjustment of 
therapy for patients with type 2 diabetes mellitus (T2DM) recommends as tier 1 those 
treatments that have been shown to be well validated and that represent the most 
well-established and effective strategies.1 Tier 1/step 1 interventions recommended by 
ADA/EASD are lifestyle changes (to decrease weight and increase activity) and met-
formin therapy. If these interventions fail to achieve or sustain glycemic goals within 
2–3 months, the recommended tier 1/step 2 intervention is to initiate treatment with 
insulin (intermediate or long-acting basal insulin) or a sulfonylurea. Adding or using Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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other antidiabetes therapies is considered a tier 2 interven-
tion (ie, a less well-validated treatment strategy). The ADA/
EASD algorithm recommends the rapid addition of medica-
tions and transition to new regimens when target glycemic 
goals are not achieved or sustained, including the early 
addition of insulin therapy.1
The ADA 2011 “Standards of medical care” support 
using the ADA/EASD algorithm but prioritize treatments that 
achieve and maintain glycemic targets safely over the use 
of specific drug therapies in the exact algorithm sequence.2 
Basal insulin therapy is regarded as the foundation insulin 
for building glycemic control, especially as a once-daily 
regimen. Currently available basal insulin therapies include 
intermediate-acting neutral protamine Hagedorn (NPH) and 
the long-acting basal insulin analogs glargine and detemir. 
NPH insulin is a crystalline suspension of human insulin 
with protamine and zinc that provides an intermediate-acting 
insulin with a slower onset of action and a longer duration 
of activity than regular human insulin.3 NPH insulin is used 
for the treatment of patients with T2DM or type 1 diabetes 
mellitus (T1DM). It has a peak of activity in 5–10 hours, 
resulting in a higher incidence of postprandial hypogly-
cemia than the long-acting insulin analogs, which display 
no peak effect.4 NPH insulin has an effective duration of 
12–18 hours, and thus is administered twice daily for most 
patients. Similar to all insulin formulations, NPH insulin’s 
duration of action is dependent on dose, site of injection, 
blood supply, temperature, and physical activity.3 The addi-
tion of insulin to the treatment regimen of patients with 
T2DM is considered a step 2 option;1 however, because of 
the higher incidence of postprandial hypoglycemia and the 
need for twice-daily dosing, NPH is usually considered after 
longer-acting insulins.
Long-acting insulins such as glargine and detemir are 
effective for basal control of glucose, but do not target 
glucose fluctuations that occur after a meal.5 Rapid-acting 
insulins are more effective at controlling postprandial 
glucose concentrations. This is the rationale for adding 
rapid-acting bolus insulin before meals in patients receiving 
long-acting basal insulin who are above target postprandial 
glucose levels.
Glargine is a recombinant long-acting insulin analog 
that is US Food and Drug Administration (FDA) approved 
for patients with T2DM and T1DM.6 Molecular changes 
allow glargine to form microprecipitates in the neutral pH 
of subcutaneous tissue, and glargine is slowly released from 
these precipitates over the dosing interval. In patients with 
T2DM, subcutaneous absorption of insulin glargine was 
two to three times slower than NPH insulin as determined 
by   disappearance of radio-labeled glargine from the injection 
site.7 For insulin glargine vs NPH insulin, the median time 
for 25% of the radioactivity to disappear was 15 vs 6.5 hours 
and for 75% to disappear was 42.4 vs 26.6 hours,   respectively. 
The duration of action of subcutaneously administered 
glargine is up to 24 hours and it is administered once daily 
in most patients.6
Twice-daily dosing of glargine has been evaluated in 
patients with T1DM.8–10 According to a review by   Devries 
et al glargine and detemir administered once daily both 
display a dose-dependent waning of glycemic effect, which 
necessitates twice-daily administration in some patients with 
T1DM.11 The rationale for this is that long-acting insulins 
administered once daily provide glycemic control for basal 
glucose production. All insulins display a dose-dependent 
effect and a relative dose-dependent duration of action. If 
the basal insulin dose is split, the total twice-daily dose 
of insulin is likely to be higher than the once-daily dose 
because the long-acting insulin will provide coverage for 
both basal and predinner glucose concentrations. To avoid 
twice-daily dosing of a basal insulin, a rapid-acting insulin 
should be added to the insulin regimen to cover prandial 
glucose concentrations.11 Although only reported for glargine 
in T1DM patients, a waning of glycemic effect requiring 
twice-daily administration likely occurs in patients with 
T2DM as well.11
Detemir is a biosynthetic long-acting insulin analog 
that is FDA-approved for patients with T2DM or T1DM. 
It is structurally modified to self-associate and bind revers-
ibly to albumin and is soluble at a neutral pH.12,13 These 
characteristics mediate detemir’s slow absorption from the 
subcutaneous administration site and result in a protracted 
duration of action compared with conventional human insu-
lin formulations. Detemir has a duration of action of up to 
24 hours.14 It is soluble in subcutaneous tissue, which may 
be why detemir has reduced inter- and intrapatient variability 
compared with other agents, since precipitation and dissolu-
tion of a precipitate (required for NPH and glargine absorp-
tion) are unpredictable processes.15 The detemir prescribing 
information recommends that, for patients with T2DM or 
T1DM currently receiving only basal insulin, changing the 
basal insulin to detemir can be done on a unit-to-unit basis. 
For insulin-naive patients with T2DM who are inadequately 
controlled on oral antidiabetic drugs, detemir should be 
started at a dose of 0.1–0.2 units/kg once daily in the eve-
ning or 10 units once or twice daily, and the dose adjusted 
to achieve glycemic targets.14Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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In early studies of detemir, twice-daily dosing was used 
for direct comparison of detemir to NPH insulin and to seek 
an additional indication. Recent clinical studies support once-
daily administration of detemir in combination with other 
antidiabetes therapies for most patients with T2DM. Despite 
this and the FDA-approval for once or twice-daily dosing, there 
are misconceptions that detemir should be administered twice 
daily for most patients. This review discusses studies that 
have evaluated twice-daily and once-daily dosing of detemir 
in patients with T2DM and addresses these misconceptions. 
To identify studies for this review, a search of PubMed was 
conducted for publications with the keywords “detemir,” 
“once daily,” “twice daily,” and “type 2 diabetes” using the 
limits of clinical trial, human, and English.
Detemir pharmacokinetics  
and pharmacodynamics (PK/PD)  
in T2DM patients
A randomized, double-blind, euglycemic clamp study of 
27 overweight men with T2DM was conducted to compare 
the time–action profiles of detemir and glargine insulins.16 
Using a continuous glucose monitoring system, both 
insulins displayed similar flat time–action profiles with 
no pronounced activity peaks, and a duration of action of 
up to 24 hours. Maximum glucose infusion rates (GIRmax) 
increased in linear fashion for both insulins. The GIRmax for 
detemir doses of 0.4, 0.8, and 1.4 units/kg were 0.9 ± 0.6, 
1.5 ± 0.8, and 2.4 ± 1.2 mg/kg/min, respectively. The GIRmax 
for glargine doses of 0.4, 0.8, and 1.4 units/kg were 0.8 ± 0.8, 
1.8 ± 1.6, and 2.9 ± 1.8 mg/kg/min, respectively. Both insu-
lins displayed an increase in peak and total plasma levels 
with increasing dose. The durations of action of detemir and 
glargine were similar at comparable doses. In the high-dose 
(1.4 units/kg) detemir and glargine groups, the duration 
of action was 22 ± 2.6 hours and 24 hours, respectively. 
With the clinically relevant low and medium doses (0.4 and 
0.8 units/kg), the durations of action were comparable and 
estimated to be less than 24 hours for detemir and glargine 
insulins. Durations of action for detemir and glargine at the 
0.4 units/kg dose were 12.0 ± 8.5 and 10.2 ± 7.4 hours, and 
for the 0.8 units/kg dose were 16.8 ± 6.8 and 19.4 ± 6.9 hours, 
respectively. In this analysis, duration of action was deter-
mined based on the GIR profile. Glucose clamp studies in 
patients with T2DM may not be effective in accurately detect-
ing the duration of action since the fasting plasma glucose 
(FPG) level is supported by endogenous insulin secretion. 
Glucose clamp studies are more useful in determining within-
patient variability. Detemir, an albumin-bound insulin, 
displayed significantly less within-patient variability than 
glargine (GIRmax [coefficient of variation, CV] 40% vs 147% 
for detemir and glargine, respectively; P , 0.001). Between-
patient variability was similar between groups (GIRmax [CV] 
66% vs 46% for detemir and glargine, respectively; P = not 
significant [NS]). Both insulins displayed an increase in the 
effect with increasing dose and a duration of action of up 
to 24 hours.
A more recent randomized, double-blind, crossover study 
of 29 men and women with T2DM also showed that detemir 
had a time–action profile, duration of action, and variation in 
glycemic effect similar to glargine as measured by continu-
ous glucose monitoring.17 Patients had similar mean 24-hour 
blood glucose levels (133 ± 21 vs 126 ± 20 mg/dL detemir vs 
glargine; P = 0.385) and similar basal blood glucose levels 
(105 ± 23 vs 98 ± 19 mg/dL; P = 0.204). In addition, the mean 
dose of detemir once daily was similar to the glargine once-
daily dose (26.3 vs 26.6 units/day; P = 0.837). Basal glucose 
control was achieved in all patients in a mean of 3.8 days for 
detemir and 3.5 days for glargine (P = 0.360).
PK/PD data support the efficacy of once-daily dosing of 
detemir. Questions regarding the accumulation of detemir, 
resulting in an increased metabolic effect, have also been 
addressed. According to Bott et al,18 glucose clamp data 
indicate that detemir twice daily reaches steady state after the 
second injection, with no further increase of the metabolic 
effect thereafter.
Clinical studies using detemir  
twice daily in T2DM patients
Clinical studies have used a protocol of detemir administered 
only twice daily19 or once or twice daily20–23 to assess safety 
and efficacy compared with NPH or glargine insulins.
A randomized, treat-to-target trial was conducted to 
assess the safety and efficacy of adding basal insulin therapy 
(with twice-daily detemir or NPH insulin) to suboptimal 
oral antidiabetes drug therapy.19 Insulin-naive patients with 
T2DM (n = 475) had glycosylated hemoglobin A1c (A1C) 
values decrease by 1.8% (8.6% to 6.8%) and 1.9% (8.5% to 
6.6%) in the detemir and NPH groups, respectively (P = NS). 
The risk of any type of hypoglycemic event and nocturnal 
hypoglycemia was reduced by 47% and 55%, respec-
tively, with detemir compared with NPH insulin therapy 
(P , 0.001 for both). Mean weight gain was significantly 
less with detemir (1.2 kg) than NPH insulin therapy (2.8 kg; 
P , 0.001). Detemir twice daily showed similar glycemic 
control with less hypoglycemia and less weight gain com-
pared with NPH twice daily.Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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The safety and efficacy of a basal-bolus regimen of 
detemir (once or twice daily) or NPH in combination with 
prandial insulin were compared in 505 patients with T2DM.20 
Following 26 weeks of treatment, significant reductions in 
A1C from baseline were observed in both groups (detemir 
0.2%; P = 0.004 and NPH 0.4%; P , 0.001). The number 
of injections of detemir did not significantly change A1C 
levels (P = 0.50). At the end of the treatment period, 39% 
and 61% of patients were receiving detemir once daily 
and twice daily, respectively; 41% and 59% were receiv-
ing NPH once daily and twice daily, respectively. Detemir 
administration was associated with less weight gain than 
NPH. The mean change in body weight (adjusted for base-
line weight and country) was 1.0 kg for detemir and 1.8 kg 
for NPH insulin (P = 0.017 between groups). Significantly 
less within-subject variability in day-to-day fasting self-
monitored blood glucose was reported with detemir than 
with NPH insulin. The mean self-measured FPG concen-
trations were 7.5 mmol/L (135.0 mg/dL) and 7.6 mmol/L 
(136.8 mg/dL), respectively; and standard deviation (SD) 
(CV%) were 1.3 (17.6%) and 1.4 (18.5%), respectively 
(P = 0.021).20 The reduced variability is likely due to 
more consistent release of detemir because, unlike NPH 
insulin, detemir remains in solution in subcutaneous tissue 
and does not rely on dissolution of the insulin precipitates 
for absorption.15 Less within-subject glycemic variability 
could reduce the risk of glucose excursions and the lack 
of a peak effect reduces the likelihood of postprandial 
hypoglycemic events.15
An open-label, treat-to-target trial was conducted to 
compare detemir once daily or twice daily with glargine 
(1:1:1) in a basal-bolus regimen in 319 patients with T2DM.22 
Exploratory analyses were conducted on trial completers 
(n = 257) to compare once-daily detemir to glargine. The 
mean decrease in A1C was 1.61% and 1.79% in once-
daily detemir and glargine-treated patients, respectively. 
  Overall incidence of hypoglycemia and within-patient vari-
ability were similar between groups. The mean weight gain 
was 3.1 kg and 4.2 kg for once-daily detemir completers and 
glargine-treated completers, respectively. The relative risk 
(RR) of nocturnal hypoglycemia was similar with once-daily 
and twice-daily administered detemir and glargine (once-daily 
RR 0.63 [95% confidence interval (CI) 0.37–1.06] and twice-
daily RR 1.15 [0.68–1.94]). Basal insulin doses were 0.69 and 
0.95 units/kg daily for patients receiving detemir once daily 
and twice daily, respectively; the glargine dose was 0.59 units/
kg daily. The higher basal dose in the detemir group may have 
been a result of the protocol, which allowed detemir-treated 
patients to be switched from once to twice-daily dosing based 
on an elevated predinner glucose   measurement. A post hoc 
analysis revealed that if the glargine cohort had been allowed 
to follow the same dosing protocol, 83.8% would have met 
criteria to switch to twice-daily dosing. The same analysis 
applied to the detemir group revealed that 82.7% of patients 
should have received twice-daily dosing rather than the 57.2% 
that actually did receive this regimen. Therefore, adding a 
second dose of a basal insulin because of an elevated predin-
ner glucose concentration would result in a large number of 
patients switching to a twice-daily dosing regimen that offers 
little to no clinical advantage over once-daily dosing.
A randomized, treat-to-target trial was conducted in 
582 insulin-naive patients with T2DM administered once 
or twice-daily detemir or glargine (1:1 detemir to glargine) 
in combination with oral antidiabetes drugs.21 By the end of 
the 52-week study, 45% (n = 104) of detemir-treated patients 
were receiving detemir once daily and 55% (n = 129) twice 
daily. Glycemic control was similar between groups. The 
mean A1C was 7.12% and 7.06% for patients receiving once-
daily and twice-daily detemir, respectively, and was 7.12% 
for glargine-treated patients (P = NS for detemir vs glargine). 
The mean clinic FPG was 7.27 mmol/L (130.86 mg/dL) 
and 6.73 mmol/L (121.14 mg/dL) for patients receiving 
once-daily and twice-daily detemir, respectively; and 
6.98 mmol/L (125.64 mg/dL) for glargine-treated patients 
(P = NS for detemir vs glargine). The variation in glycemic 
control prebreakfast (within-participant SD 1.06 mmol/L 
[19.1 mg/dL] vs 1.03 mmol/L [18.5 mg/dL]; P = 0.45) 
and predinner (1.60 mmol/L [28.8 mg/dL] vs 1.55 mmol/L 
[27.9 mg/dL] ; P = 0.41) was similar between detemir and 
glargine groups, respectively. The mean daily dose of detemir 
was 0.52 units/kg and 1.00 units/kg for once-daily and twice-
daily dosing, respectively; the mean daily dose of glargine 
was 0.44 units/kg. Weight gain was significantly lower in 
patients administered detemir compared with glargine; the 
mean change in weight for patients who completed the study 
(n = 482) was 3.0 vs 3.9 kg, respectively (P = 0.01). Patients 
receiving once-daily detemir gained significantly less weight 
than those receiving twice-daily dosing (mean weight change 
2.3 vs 3.7 kg, respectively; P , 0.001).
A randomized, treat-to-target study compared the effi-
cacy and safety of detemir with glargine in a basal-bolus 
regimen in 385 patients with T2DM.23 At 26 weeks, detemir 
and glargine had similar A1C reductions, and results met 
the noninferiority criterion (least squares mean [detemir-
glargine]: 0.207; 95% CI, 0.0149–0.3995). At 26 weeks, 
the least squares mean (standard error, ±SE) A1C values Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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were 7.13% ± 0.073% for detemir and 6.92% ± 0.091% 
for glargine-treated patients (P = 0.035); the least squares 
mean FPG concentrations were 7.22 mmol/L (129.7 mg/dL) 
and 7.44 mmol/L (134.3 mg/dL), respectively (P = 0.397). 
Significantly less weight gain was observed in detemir 
than glargine-treated patients (1.2 ± 3.96 vs 2.7 ± 3.94 kg, 
respectively; P = 0.001). The risk of hypoglycemia was 
comparable between groups and there was no difference in 
within-patient variability. Detemir once daily was the regi-
men used in 87.4% throughout the study. The mean doses of 
insulin were similar between groups (0.81 and 0.75 units/kg 
for detemir and glargine, respectively; P = 0.1).
Taken together, the results of these studies suggest that, 
initially, basal insulin (including detemir) may be adminis-
tered once daily and that the dose should be increased until 
the desired FPG level has been achieved.24 If the desired 
predinner target blood glucose level cannot be achieved, the 
total dose of basal insulin may be divided and administered 
as two separate injections (morning and evening). However, 
twice-daily dosing of a basal insulin may not provide the 
needed glycemic and clinical benefits, and the general under-
standing is that once-daily dosing is preferred by patients and 
is associated with better medication adherence than more 
frequent dosing.5
Optimizing detemir therapy: 
designs of clinical studies utilizing 
detemir once daily in T2DM
More recent studies evaluating detemir in patients with 
T2DM have tended to use basal-bolus regimens for patients 
with limited or no β-cell function and basal-oral therapy 
for patients initiating insulin. Most of these detemir studies 
evaluated once-daily dosing.25–29 All studies discussed below 
are randomized controlled studies except for Predictable 
Results and Experience in Diabetes through Intensification 
and Control to Target: an International Variability Evaluation 
(PREDICTIVE), which is an observational study.
Three randomized, controlled studies evaluated the effi-
cacy of once daily. The first, PREDICTIVE BMI,27 was a 
26-week, randomized, controlled trial of 277 overweight or 
obese adults with uncontrolled T2DM (A1C 7.5%–11.0%, 
body mass index [BMI] 25–40 kg/m2). Patients received 
either detemir or NPH insulin in the evening and insulin 
aspart at main meals and were allowed to continue taking 
metformin. At 26 weeks, equivalent glycemic control was 
reported for both treatment groups. The mean A1C value 
decreased from 8.9% to 7.8% with once-daily detemir 
and from 8.8% to 7.8% with NPH insulin therapy (P = NS 
between-treatment difference). The mean FPG concentra-
tion decreased to 8.8 ± 2.7 mmol/L (158.7 ± 48.6 mg/dL) 
and 8.9 ± 3.1 mmol/L (160.2 ± 55.8 mg/dL) in the detemir 
and NPH groups, respectively (P = NS between-treatment 
  difference).   However, significantly less weight gain 
(0.4 kg) was reported with detemir than with NPH (1.9 kg; 
P , 0.0001), and the risk of a hypoglycemic event was sig-
nificantly lower with detemir compared with NPH (RR 0.62 
[all events] and 0.43 [nocturnal]; P , 0.0001 for both). The 
authors concluded that once-daily detemir was effective as 
part of a basal-bolus regimen for patients with T2DM.
In the second study, a randomized, open-label, multi-
center trial of 504 patients with poorly controlled T2DM 
was conducted at 91 centers across Europe and the USA.28 
Patients were randomized to either once-daily morning 
detemir, once-daily evening detemir, or once-daily evening 
NPH (1:1:1) for 20 weeks. Glycemic control was similar 
among the detemir and NPH groups, with significantly 
better glycemic control with evening compared with morn-
ing detemir administration. The end of study mean A1C 
values were 7.5%, 7.4%, and 7.35% for morning detemir, 
evening detemir, and evening NPH, respectively; and the 
mean FPG was 8.61 mmol/L (154.98 mg/dL), 7.17 mmol/L 
(129.06 mg/dL), and 7.77 mmol/L (139.86 mg/dL), respec-
tively (P , 0.001 morning vs evening detemir). Compared 
with NPH, evening detemir resulted in 53% (P = 0.019) 
and 65% (P = 0.031) less 24-hour and nocturnal hypogly-
cemia, respectively. Evening detemir and NPH insulin led 
to a weight gain of 0.7 and 1.6 kg, respectively (P = 0.005). 
Results indicate that detemir given once daily improves 
glycemic control similar to NPH but may be better tolerated 
at comparable doses.
The third trial, Treat to Target with Once-daily Insulin 
Therapy: Reduce A1C by Titrating Effectively (TITRATE)29 
is a 20-week, randomized, controlled, open-label, multi-
center, treat-to-target study. Insulin-naive patients (n = 244) 
with T2DM received once-daily detemir therapy and were 
randomized to one of two treatment arms, with doses titrated 
to achieve target FPG concentrations of 70–90 mg/dL 
(3.9–5.0 mmol/L) or 80–110 mg/dL (4.4–6.1 mmol/L). 
Once-daily detemir dosing followed the patient self-adjusted 
algorithm (303 algorithm) described below. The major-
ity of patients in both groups achieved the ADA target 
A1C of ,7% by the end of the study (64.3% and 54.5% 
for the 70–90 mg/dL [3.9–5.0 mmol/L] or 80–110 mg/
dL [4.4–6.1 mmol/L] groups, respectively), and overall, 
low rates of hypoglycemia were reported (7.73 and 5.27 
events/patient/year, respectively). Lowering the fasting Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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glucose levels using a self-directed titration algorithm with 
once-daily detemir was associated with low rates of hypo-
glycemia and increased the likelihood of achieving the 
target A1C level. By the end of study, the A1C value in the 
70–90 mg/dL arm was 6.77%, which is the lowest end of 
study A1C in a treat-to-target trial with any once-daily basal 
analog therapy.
Recently, the addition of prandial (bolus) insulin and 
detemir to oral therapy was evaluated. The Treat to Target 
in Type 2 Diabetes (4-T) study is a 3-year, open-label, mul-
ticenter trial of 708 patients randomly assigned to receive 
biphasic insulin aspart twice daily, prandial insulin aspart 
three times daily, or basal detemir once daily (or twice, if 
required), added to suboptimal therapy with metformin 
and a sulfonylurea.30 Most patients required the addition 
of aspart in the second and third year of study. All patients 
treated with basal and prandial insulin-based regimens (such 
as detemir + aspart) achieved better A1C control than those 
receiving biphasic insulin therapy by the end of study. The 
median A1C levels (6.9%; 95% CI 6.8%–7.1%; P = 0.28 
overall comparison) were similar after 1 year of use for all 
groups and remained stable at the end of the study. Among 
patients with a baseline A1C # 8.5%, patients in the 
biphasic group were less likely to achieve an A1C # 6.5% 
compared with those in the prandial group (odds ratio 
[OR] 0.48; 95% CI 0.28–0.82; P = 0.007) or basal group 
(OR 0.46; 95% CI 0.27–0.78; P = 0.004). Detemir therapy 
was associated with fewer hypoglycemic events. Median 
numbers of hypoglycemic events per patient per year dur-
ing the study were biphasic group, 3; prandial group, 5.5; 
and detemir group, 1.7. After 3 years, less weight gain 
was observed in the basal group (3.6 ± 0.5 kg) than in the 
biphasic (5.7 ± 0.5 kg) or prandial (6.4 ± 0.5 kg) insulin 
groups (P , 0.01 for biphasic vs basal and prandial vs 
basal groups). More patients in the biphasic insulin group 
were taking sulfonylurea therapy at the end of the study 
compared with the other study groups, which may explain 
the increased weight gain and hypoglycemic events and 
smaller A1C reduction in the biphasic group. The median 
daily insulin dose increased during the second and third 
study years and was similar for patients receiving prandial 
or basal insulin therapy (105 units/day [95% CI 91–119] vs 
105.5 units/day [95% CI 90–212], respectively; P = 0.26). 
After 1 year, about two thirds of patients receiving detemir 
were maintained with once-daily injections.31 Most patients 
required the addition of prandial insulin by the second and 
third year of study.30 Perhaps if more patients had received 
basal-bolus therapy during the first year of therapy, more 
patients could have achieved the A1C target of #6.5%, 
fewer patients could have received twice-daily dosing, 
and the mean total daily detemir dose could have been 
lower. Overall, study results provide good evidence of the 
effectiveness and safety of once-daily detemir. In addition, 
data suggest that starting with a basal insulin instead of a 
bolus insulin is a better treatment option before intensifi-
cation to a basal-bolus regimen because, with comparable 
glycemic control, patients exhibited less weight gain and 
less hypoglycemia.30
PREDICTIVE was a large-scale, multinational, open-
label, prospective, observational study of 19,911 patients 
with T1DM or T2DM assessing the safety and efficacy of 
detemir in day-to-day clinical practice.32 Subgroup analyses 
of the European PREDICTIVE cohorts have been released 
(see Table 1).33–36 Overall, study results indicate that once-
daily detemir effectively controls A1C and is associated with 
less weight gain than other regimens evaluated.
PREDICTIVE 30325 was a 26-week, multicenter, open-
label, randomized study of 5604 patients, which compared 
glycemic control and safety with detemir therapy using 
a patient self-adjusted dosing algorithm (303 algorithm 
group) to standard-of-care physician-driven adjusted dos-
ing (standard-of-care group). Subjects in the 303 algorithm 
group were instructed to make insulin dose adjustments as 
follows: mean FPG , 80 mg/dL, reduce detemir dose by 
3 U; mean FPG between 80 and 110 mg/dL, no change; 
mean FPG . 110 mg/dL, increase detemir dose by 3 U, 
hence the name 3-0-3. At 26 weeks, 91% of the patients 
in the 303 algorithm group and 85% in the standard-  of-
care group remained on once-daily detemir, based on the 
mean of three consecutive FPG values, which suggests that 
detemir is effective as a once-daily dosing regimen. In the 
small subgroup that received twice-daily detemir, glycemic 
control was found to be not as good as the once-daily group 
despite the detemir dose for the twice-daily subgroup being 
approximately two times the dose used in the once-daily 
subgroup. Mean A1C values decreased by 0.6% (from 8.5% 
to 7.9%) for the 303 algorithm group and by 0.5% (from 
8.5% to 8.0%) for the standard-of-care group (P = 0.0106 
between groups). The mean FPG values decreased by 
34 mg/dL (from 175 to 141 mg/dL) for the 303 algorithm 
group and by 22 mg/dL (from 174 to 152 mg/dL) for the 
standard-of-care group (P , 0.0001 between groups). 
Mean body weight did not change significantly for either 
group during the study (+0.1 kg for the algorithm group 
and −0.2 kg for the standard-of-care group; P = NS). By 
the end of the study, the dose of detemir was greater in the 
algorithm group (0.64 units/kg) than the standard-of-care 
group (0.46 units/kg), suggesting that the algorithm may Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Summary of PReDiCTive subgroup analyses by country/region for type 2 diabetes patients
Cohort Patients, duration, and treatment Results
French33 N = 329 
52 weeks 
Detemir + OAD (n = 263)  
or detemir + bolus insulin  
(n = 66)
•   Once-daily detemir + OAD change from baseline in A1C was −1.01% ± 1.48%;  
BiD dosing  was −0.66% ± 1.51% (P , 0.01 for both)
•   Once-daily detemir + bolus insulin change from baseline in A1C was −0.73% ± 1.78%  
(P = 0.019); BID dosing was −0.22% ± 0.87% (P = NS )
•   Once-daily detemir + OAD change from baseline in FPG was −2.73 ± 3.07 mmol/L  
(−49.14 ± 55.26 mg/dL) (P , 0.0001); BID dosing was −0.10 ± 2.66 mmol/L  
(−1.8 ± 47.88 mg/dL) (P = NS)
•   Once-daily detemir + bolus insulin change from baseline in FPG was  
−1.88 ± 4.81 mmol/L (−33.84 ± 86.58 mg/dL) (P = 0.062); BID dosing was  
−1.02 ± 2.44 mmol/L (−18.38 ± 43.92 mg/dL) (P = NS )
•   Once-daily detemir + OAD change in weight from baseline was 0.0 ± 4.9 kg;  
BiD dosing was −0.2 ± 3.9 kg (P = NS for both)
•   Once-daily detemir + bolus insulin change in weight from baseline was 1.0 ± 4.8 kg;  
BiD dosing was 0.1 ± 7.2 kg (P = NS for both)
•   Once-daily detemir + OAD change in total hypoglycemia events/patient/year  
from baseline was −7.02 (P = 0.0014); BID dosing was −8.58 (P = NS)
•   Once-daily detemir + bolus insulin change in total hypoglycemia events/patient/year  
from baseline was −1.43; BID dosing was −15.99 (P = NS for both)
•   Once-daily detemir + OAD associated with lower total detemir dose  
(0.35 ± 0.16 units/kg) than BID detemir dosing (0.74 ± 0.30 units/kg) at end of study
•   84% (222/263) of detemir + OAD-treated patients received once-daily detemir;  
none were converted to BiD
•   84% (37/44) of detemir + bolus-treated patients who started on once-daily  
detemir were receiving this regimen at the end of the study
German34 N = 1832 
3 months 
Transferred to detemir ± OAD  
from an OAD-only (n = 1321),  
NPH ± OAD (n = 251),  
or glargine ± OAD (n = 260)
•   Change in A1C from baseline for switch from OAD-only was −1.29% ± 0.03%, for  
NPH ± OAD was −0.60% ± 0.09%, and for glargine was −0.59% ± 0.06% (P , 0.0001 for all)
•   Change in FPG for OAD-only was −3.22 ± 0.67 mmol/L (−58.1 ± 1.2 mg/dL), for  
NPH ± OAD was −1.62 ± 0.18 mmol/L (−29.1 ± 3.2 mg/dL), and for glargine ± OAD  
was −1.37 ± 0.16 mmol/L (−24.6 ± 2.8 mg/dL) (P , 0.0001 for all)
•   Change in weight for OAD-only was −0.9 ± 0.1 kg, for NPH ± OAD was −0.9 ± 0.3 kg,  
and for glargine ± OAD was −0.8 ± 0.2 kg (P , 0.01 for all)
• Change in total hypoglycemic events/patient/year was −2.7 (P , 0.0001) 
• Once-daily detemir was used in 79% of patients
Danish35 N = 77 
3 months 
Detemir + bolus insulin
• Change in A1C from baseline was −0.3% ± 1.1% (P = NS) 
• Change in FPG was −2.7 ± 3.9 mmol/L (48.6 ± 70.2 mg/dL) (P = NS) 
• Change in weight was −1.0 kg (P = 0.04) 
•   Mean change in the incidence of total hypoglycemic episodes was −17.7  
episodes/patient/year (P = 0.0012)
•   Detemir used once daily in 49% and twice daily in 34% of patients; data  
were missing for remaining patients
european36 N = 2377 
14.4 weeks 
Detemir ± OADs,  
insulin-naive
• Change in A1C from baseline was −1.3 ± 1.3% (P , 0.0001) 
• Change in FPG/FBGa was −3.7 ± 3.3 mmol/L (−66.6 ± 59.4 mg/dL) (P , 0.0001)
•   within-subject FPG/FBGa variability was −0.5 ± 1.2 mmol/L (−9.0 ± 21.6 mg/dL) (P , 0.0001)
•   Change in body weight was −0.7 ± 3.5 kg (P , 0.0001); reductions in body weight most 
apparent in patients with a higher baseline BMi
• 13% of patients reported weight loss of .3 kg at the end of study 
• Change in mean number of hypoglycemic episodes per patient year was −0.3 (P = 0.27) 
• Mean daily dose of detemir was 22 units 
• Detemir used once daily in 82% of patients
Note: aFasting blood glucose or fasting plasma glucose, depending on glucose meter used.
Abbreviations: AiC, glycosylated hemoglobin A1c; BID, twice daily; BMI, body mass index; FBG, fasting blood glucose; FPG, fasting plasma glucose; NS, not significant; OAD, 
oral antidiabetes drug; PREDICTIVE, Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation.
be more effective at adjusting the insulin regimen than 
standard-of-care practices. Hypoglycemia rates decreased 
significantly from baseline to end of study, from 9.05 
to 6.44 events/patient/year for the 303 algorithm group 
(P , 0.0039) and from 9.53 to 4.95 for the standard-of-
care group (P , 0.0001)]. Results from PREDICTIVE 
303 indicate that self-adjusted dosing and once-daily dosing 
of detemir is effective.Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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A post hoc subgroup analysis that evaluated insulin-
naive patients in the PREDICTIVE 303 study found that 
by study end, 95% of patients in the 303 algorithm group 
remained on once-daily detemir and were able to effectively 
implement the 303 algorithm to achieve improvements in 
glycemic   control.26 These results are consistent with the 
findings from the observational PREDICTIVE study con-
ducted in Europe.
Two additional subgroup analyses of European cohorts 
of PREDICTIVE were conducted and suggested that switch-
ing to once-daily detemir from NPH or glargine therapy is 
associated with significantly improved glycemic control. In 
a cohort of 777 patients with T2DM, Yenigun and Honka 
found that switching from once or twice-daily glargine to 
once-daily detemir was associated with a significant reduc-
tion in A1C from baseline (0.51% and 0.89%, respectively; 
P , 0.05 for both groups).37 The mean reduction in FPG 
was significant in the once-daily and twice-daily to once-
daily transition groups (1.63 ± 2.42 [29.3 ± 43.56] and 
1.91 ± 2.35 [34.4 ± 42.3] mmol/L [mg/dL], respectively; 
P , 0.05). The mean reduction in body weight from baseline 
was significant in the once-daily to once-daily transition 
group (0.3 ± 3.2 kg; P , 0.05) but not in the twice-daily to 
once-daily transition group (0.3 ± 1.7 kg; P = NS). Similar 
results were observed by Sreenan et al, when transition-
ing from NPH to once-daily detemir.38 A cohort of 2137 
patients with T2DM was evaluated. The mean reduction in 
A1C was 0.56% for both groups (P , 0.001 from baseline 
for both) transitioning from once or twice-daily NPH. 
The mean change from baseline in FPG was significantly 
reduced when patients transitioned from NPH to detemir 
(1.63 [29.34] and 1.91 [34.38] mmol/L [mg/dL] for the 
once-daily to once-daily and the twice-daily to once-daily 
transition groups, respectively; P , 0.05 for both groups). 
Switching to once-daily detemir from once-daily NPH 
decreased the overall rate of hypoglycemic events by 10.2 
episodes/patient year (P , 0.001) and from twice-daily 
NPH it decreased the rate by 11.3 (P , 0.001). The daily 
dose of detemir at the end of study was 8.1 units less per 
day than the prestudy NPH twice-daily dose, and was 4 units 
higher than the prestudy NPH once-daily dose.
The significant reduction in weight observed with 
detemir in comparison to NPH in clinical studies has not 
been explained by differences in the incidence of hypo-
glycemia or dose,39 and the mechanisms underlying the 
positive weight effects of detemir compared with NPH or 
glargine are currently unknown. Hypotheses include that 
insulin detemir may affect satiety signaling and energy 
homeostasis or that detemir’s albumin-binding proper-
ties may allow a greater exposure of detemir to the liver 
and less to peripheral   adipose tissue, which could limit 
adipogenesis.40,41 However, these findings have not been 
confirmed and the proposed mechanisms are so specula-
tive and so varied in nature that researchers are unsure 
as to which direction to follow to further elucidate the 
question.
Questions regarding the association of long-acting insu-
lin analogs and induction of cancer have been investigated. 
According to a 2010 consensus statement issued by the 
ADA and the American Cancer Society (ACS),42 cancer 
and diabetes are diagnosed within the same individual 
more frequently than would be expected by chance, even 
after adjusting for age. The statement notes that, accord-
ing to preliminary evidence, an association exists between 
exogenous insulin and increased cancer risk, and identifies 
a series of “widely publicized” epidemiologic analyses 
that examined a potential association between cancer and 
insulin use and/or use of the long-acting insulin analog 
glargine. The statement acknowledges the likelihood that 
confounding by unmeasured or incompletely measured risk 
factors may explain at least in part the reported associations 
between insulin and increased cancer risk, and describes 
a 5-year trial43 of glargine vs NPH (n = 1017) that did not 
find evidence of excess cancer risk with glargine, although 
the number of cancer endpoints (57 glargine, 62 NPH), the 
statement notes, was small. The ADA/ACS statement ulti-
mately recommends that cancer risk should not be a major 
factor in choosing between available diabetes therapies for 
the average patient. A meta-analysis by Dejgaard et al,44 not 
cited in the position statement, evaluated data from 8693 
patients with type 1 or type 2 diabetes enrolled in random-
ized and controlled diabetes trials of at least 12 weeks in 
duration that compared detemir with NPH or glargine. The 
estimated OR for a cancer diagnosis between NPH and 
detemir was statistically significant and favored detemir. 
There was a more than twofold higher cancer occurrence 
in the NPH-treated population compared with detemir and 
a similar occurrence of a cancer diagnosis compared with 
glargine.
Holistic approach to T2DM 
management
Evidence supports a holistic approach to diabetes manage-
ment using multidisciplinary teams that include a diabetes Clinical Pharmacology:   Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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specialist nurse, psychologist, nutritionist, and pharmacist 
to best address the complex medical care of patients with 
T2DM.45 The Global Partnership for Effective Diabetes 
Management is a multidisciplinary group of international 
diabetes experts that strives to provide guidance and sup-
port for diabetes management teams to help more patients 
achieve treatment goals. The group is focused on increasing 
awareness of current treatment guidelines and encouraging 
implementation of these guidelines in the clinical practice 
setting. A holistic approach is one of the 10 key practical 
recommendations of the Global Partnership for Effective 
Diabetes Management. In addition to controlling hyperg-
lycemia, therapies directed at controlling other coexisting 
conditions of T2DM, such as dyslipidemia, hypertension, and 
obesity, may decrease the risk of developing microvascular 
and cardiovascular complications.2 Selecting therapies that 
minimize weight gain may help to reduce the barriers that 
prevent patients with T2DM from initiating or complying 
with insulin therapy (described in detail in a 2009 review 
by FX Pi-Sunyer)46 and support a holistic approach to treat-
ment. Multidisciplinary group members should encourage 
structured patient education and self-care so responsibility 
for achieving agreed glucose and comorbid condition treat-
ment goals is shared.45
Conclusion
Protocols for some earlier clinical studies of detemir evalu-
ated twice-daily dosing of detemir; this may have influenced 
clinical practice and clinician perception that detemir should 
be prescribed this way for all patients. However, detemir 
is FDA-approved for once-daily dosing in patients with 
T2DM or T1DM.14 The efficacy, safety, and feasibility 
of once-daily dosing of detemir are supported by glucose 
clamp study data and clinical trials.16,25,27–29 Results from the 
European cohorts of the observational PREDICTIVE study 
indicate that once-daily detemir is more commonly used in 
clinical practice than twice-daily dosing.34,36,47,48 In addition, 
once-daily detemir is as effective as twice-daily dosing in 
providing glycemic control and generally requires the use of 
less detemir insulin.25,33 Data show that once-daily detemir 
controls A1C and is associated with no weight gain or less 
weight gain than comparator regimens. Weight gain could 
make it more difficult to achieve glycemic control and exac-
erbate preexisting cardiovascular risk factors. Involvement 
of a multidisciplinary team and using a holistic approach 
for the treatment of T2DM patients are recommended to 
achieve and maintain the best patient outcomes. Adding a 
prandial insulin to the regimen before considering detemir 
twice daily may provide better glycemic control for patients 
who have not achieved glycemic control with a basal dose 
of once-daily detemir.
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